A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2018
At a glance
- Drugs Momelotinib (Primary) ; Ruxolitinib
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Registrational; Therapeutic Use
- Acronyms Simplify 1
- Sponsors Gilead Sciences
- 03 Dec 2018 Results presented in the Sierra Oncology media release.
- 03 Dec 2018 According to a Sierra Oncology media release, results from this study are being presented today at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition.
- 27 Nov 2018 According to a Sierra Oncology media release, results from this study will be presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History